MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574783 | Name: MIM1
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MIM1 is an inhibitor of Mcl-1, an antiapoptotic Bcl-2 family protein that selectively engages the canonical groove of Mcl-1, inhibiting its ability to bind BH3 domains. MIM1 induces caspase-3/7 activation and cell death in Mcl-1-dependent leukemia cells.

Chemical Structure

MIM1
MIM1
CAS#509102-00-5

Theoretical Analysis

MedKoo Cat#: 574783

Name: MIM1

CAS#: 509102-00-5

Chemical Formula: C17H21N3O3S

Exact Mass: 347.1304

Molecular Weight: 347.43

Elemental Analysis: C, 58.77; H, 6.09; N, 12.09; O, 13.81; S, 9.23

Price and Availability

Size Price Availability Quantity
10mg USD 405.00 2 Weeks
50mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MIM1
IUPAC/Chemical Name
4-[[[2-(cyclohexylimino)-4-methyl-3(2H)-thiazolyl]imino]methyl]-1,2,3-benzenetriol
InChi Key
RGGFUBMUOVFZEF-LDRVEFRDSA-N
InChi Code
InChI=1S/C17H21N3O3S/c1-11-10-24-17(19-13-5-3-2-4-6-13)20(11)18-9-12-7-8-14(21)16(23)15(12)22/h7-10,13,21-23H,2-6H2,1H3/b18-9+,19-17+
SMILES Code
OC1=CC=C(/C=N/N2/C(SC=C2C)=N/C3CCCCC3)C(O)=C1O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MIM-1 is an inhibitor of myeloid cell factor 1 (Mcl-1).
In vitro activity:
Changes in the expression of apoptosis-associated genes (n=93) in two human brain cell lines after treatment with the apoptosis inhibitors ABT-737 and MIM-1 (individually), between the apoptosis inhibitor treated group and the control group, were determined using a commercially pre-designed microfluidic array. Significant changes in apoptotic gene expression with more than a 2.0-fold difference in their expression levels were obtained in both cell lines; the most altered genes were in the HA cell line after MIM-1 treatment (n=42). Reference: Oncol Rep. 2016 Dec;36(6):3188-3196. https://pubmed.ncbi.nlm.nih.gov/27779684/
In vivo activity:
TBD
Solvent mg/mL mM comments
Solubility
DMF:PBS (pH 7.2) (1:6) 0.1 0.40
DMSO 35.0 100.74
Ethanol 0.1 0.35
DMF 30.0 86.35
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 347.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Respondek M, Beberok A, Rzepka Z, Rok J, Wrześniok D. Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes. Pathol Oncol Res. 2020 Jul;26(3):1465-1474. doi: 10.1007/s12253-019-00715-z. Epub 2019 Aug 20. PMID: 31432325; PMCID: PMC7297871. 2. Vidomanova E, Racay P, Pilchova I, Halasova E, Hatok J. Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines. Oncol Rep. 2016 Dec;36(6):3188-3196. doi: 10.3892/or.2016.5191. Epub 2016 Oct 21. PMID: 27779684.
In vitro protocol:
1. Respondek M, Beberok A, Rzepka Z, Rok J, Wrześniok D. Mcl-1 Inhibitor Induces Cells Death in BRAF-Mutant Amelanotic Melanoma Trough GSH Depletion, DNA Damage and Cell Cycle Changes. Pathol Oncol Res. 2020 Jul;26(3):1465-1474. doi: 10.1007/s12253-019-00715-z. Epub 2019 Aug 20. PMID: 31432325; PMCID: PMC7297871. 2. Vidomanova E, Racay P, Pilchova I, Halasova E, Hatok J. Microfluidic profiling of apoptosis-related genes after treatment with BH3-mimetic agents in astrocyte and glioblastoma cell lines. Oncol Rep. 2016 Dec;36(6):3188-3196. doi: 10.3892/or.2016.5191. Epub 2016 Oct 21. PMID: 27779684.
In vivo protocol:
TBD
1. Cohen, N.A., Stewart, M.L., Gavathiotis, E., et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem. Biol. 19(9), 1175-1185 (2012).